Aurora Cannabis (ACB, $6.85) misses fiscal Q3 expectations
Aurora Cannabis posted its fiscal third quarter results that fell short of analysts’ expectations.
For the third quarter ended March 31, the cannabis company reported a loss of -C$0.85 a share, wider than the -C$0.25 a share loss anticipated by analysts polled by FactSet. The company’s revenue came in at C$55.2 million, compared to C$68.7 million expected by analysts.
Aurora also said that it plans to file for a new US$300 million at-the-market stock sale program. According to the company, the program would “provide maximum flexibility to pursue select acquisitions going forward, including within the U.S.”
Momentum Indicator for ACB turns negative, indicating new downward trend
ACB saw its Momentum Indicator move below the 0 level on April 07, 2022. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 74 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Current price $2.84 crossed the resistance line at $2.68 and is trading between $20.45 resistance and $2.68 resistance lines. Throughout the month of 04/12/22 - 05/13/22, the price experienced a -21% Downtrend, while the week of 05/06/22 - 05/13/22 shows a +1% Uptrend.
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on May 05, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day Moving Average for ACB crossed bearishly below the 50-day moving average on April 12, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ACB entered a downward trend on May 13, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACB's RSI Indicator exited the oversold zone, 33 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +24.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 190 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ACB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 65%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.18.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.406) is normal, around the industry mean (6.265). P/E Ratio (0.000) is within average values for comparable stocks, (57.204). ACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.450). ACB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (3.149) is also within normal values, averaging (105.202).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
The average market capitalization across the Pharmaceuticals: Other Industry is 1.7B. The market cap for tickers in the group ranges from 246 to 77.8B. ZTS holds the highest valuation in this group at 77.8B. The lowest valued company is PEMTF at 246.
The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -3.3%. For the same Industry, the average monthly price growth was -12.28%, and the average quarterly price growth was -28.86%. SYUP experienced the highest price growth at 325%, while HDRPF experienced the biggest fall at -94.89%.
- 5/10/22 5:36 AM: Aurora Cannabis (ACB, $2.53) is a top weekly loser for penny stocks, falling -19.43%
- 5/5/22 4:57 AM: Aurora Cannabis (ACB, $3.19) was a top weekly gainer, with a +8.5% jump
- 3/29/22 5:17 AM: Aurora Cannabis (ACB, $4.09) was a top weekly gainer, with a +17.87% jump. Expect an Uptrend reversal
The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -60.09%. For the same stocks of the Industry, the average monthly volume growth was -88.76% and the average quarterly volume growth was -78.27%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Negative Outlook today, backed by the Aroon Indicator. Tickeron has a negative outlook on this group and predicts a further decline by more than 4.00% within the next month with a likelihood of 72%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.27.
45 stocks in the group of tickers confirmed the negative outlook based on the MA50MA10 indicator with average odds of 83%.
The most notable companies in this group are Archer Daniels Midland Company (NYSE:ADM), Elanco Animal Health (NYSE:ELAN), Canopy Growth Corp (NASDAQ:CGC), Tilray Brands (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB).
The average market capitalization across the group is 1.1B. The market cap for tickers in the group ranges from 0 to 48B. ADM holds the highest valuation in this group at 48B. The lowest valued company is CHSCL at 0.
The average weekly price growth across all stocks in the group was -3.01%. For the same group, the average monthly price growth was -16.19%, and the average quarterly price growth was -34.8%. EOFBF experienced the highest price growth at 204.88%, while URYL experienced the biggest fall at -48.12%.
- 5/14/22 4:23 AM: Cronos Group (CRON, $3.27) was a top weekly gainer, with a +10.47% jump
- 5/14/22 4:23 AM: Nascent Biotech (NBIO, $0.11) was a top loser this week, declining -14.64%. Expect a Downtrend continuation
- 5/14/22 4:22 AM: Lowell Farms (LOWLF, $0.29) was a top weekly gainer, with a +28.22% jump
The average weekly volume growth across all stocks in the group was 1132.86%. For the same stocks of the group, the average monthly volume growth was 945.95% and the average quarterly volume growth was 329.24%
- 5/12/22 5:33 AM: The volume for Unrivaled Brands stock increased for four consecutive days, resulting in a record-breaking daily growth of 105% of the 65-Day Volume Moving Average
- 5/6/22 4:59 AM: The volume for MGP Ingredients stock increased for one day, resulting in a record-breaking daily growth of 314% of the 65-Day Volume Moving Average
- 4/19/22 4:03 AM: The volume for Unrivaled Brands stock increased for one day, resulting in a record-breaking daily growth of 477% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows